Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center

Muhammet Cengiz; Ayşe Nuransoy Cengiz; Oktay Bozkurt; Mevlüde İnanç; Metin Özkan

Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center

Abstract

Aims: Fifty percent of patients with metastatic renal cell carcinoma (RCC) die within the first year. Therefore, survival in the first-line setting is of paramount importance. Cabozantinib has been introduced for use in the first-line setting. We plan to conduct a study on its contribution to survival in Turkiye's population. Methods: A total of 108 patients with metastatic RCC were stratified according to whether they received sunitinib or cabozantinib. The two groups were similar in terms of their demographic characteristics. Survival outcomes and prognostic factors influencing survival were analyzed. Results: Overall survival was superior in the cabozantinib group, with a median of 21 months in sunitinib versus 47 months in cabozantinib group. International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score and cabozantinib treatment were identified as independent prognostic factors by multivariant analysis. Conclusion: Tyrosine kinase inhibitor therapies continue to play a significant role in the treatment of metastatic RCC. In countries where combination therapy with immune checkpoint inhibitors is not available, cabozantinib is a good option and may improve survival rates.

Keywords

Supporting Institution

NO

Ethical Statement

This study protocol was approved by the Erciyes University Health Sciences Research Ethics Committee (Decision No. 2026/69), with a waiver of informed consent waivrf due to its retrospective nature. All procedures were conducted in accordance with the ethical standards of the institutional and national research committees on human experimentation and with the 1975 Declaration of Helsinki, as revised in 2024.

Thanks

The authors thank the Editing Office of the Dean for Research at Erciyes University for proofreading this manuscript.

References

Makino T, Kadomoto S, Izumi K, Mizokami A. Epidemiology and prevention of renal cell carcinoma. Cancers (Basel). 2022;14(16):4059. doi:10.3390/cancers14164059
Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79-87. doi:10.14740/wjon1279
Kanwal R. Metastasis in renal cell carcinoma: biology and treatment. Adv Cancer Biol Metastasis. 2023;7:100094. doi:10.1016/j.adcanc.2023.100094
Roskoski R Jr. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res. 2017; 120:116-132. doi:10.1016/j.phrs.2017.03.010
Abdelaziz A, Vaishampayan U. Cabozantinib for renal cell carcinoma: current and future paradigms. Curr Treat Options Oncol. 2017;18(3):18. doi:10.1007/s11864-017-0444-6
Chen RC, Choueiri TK, Feuilly M, et al. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). Cancer. 2020; 126(24):5311-5318. doi:10.1002/cncr.33169
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. doi:10.1056/NEJMoa065044
Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015;21(5):1071-1077. doi:10.1158/1078-0432.CCR-14-1993

Details

Primary Language

English

Subjects

Clinical Oncology

Journal Section

Research Article

Authors

Muhammet Cengiz
0000-0002-2028-9687
Türkiye

Ayşe Nuransoy Cengiz ^*
0000-0001-9133-8602
Türkiye

Oktay Bozkurt
0000-0003-3551-5234
Türkiye

Mevlüde İnanç
0000-0002-3737-3420
Türkiye

Metin Özkan
0000-0003-0359-0504
Türkiye

Publication Date

September 11, 2026

Submission Date

June 22, 2026

Acceptance Date

August 3, 2026

Published in Issue

Year 2026 Volume: 8 Number: 5

IZ

https://izlik.org/JA48SY36XT

Cite

RIS / Bibtex

APA

Cengiz, M., Nuransoy Cengiz, A., Bozkurt, O., İnanç, M., & Özkan, M. (2026). Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center. Anatolian Current Medical Journal, 8(5), 1009-1013. https://izlik.org/JA48SY36XT

AMA

1.Cengiz M, Nuransoy Cengiz A, Bozkurt O, İnanç M, Özkan M. Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center. Anatolian Curr Med J / ACMJ / acmj. 2026;8(5):1009-1013. https://izlik.org/JA48SY36XT

Chicago

Cengiz, Muhammet, Ayşe Nuransoy Cengiz, Oktay Bozkurt, Mevlüde İnanç, and Metin Özkan. 2026. “Survival Outcomes With First-Line VEGF-Targeted Therapies in Metastatic Renal Cell Carcinoma: Real-World Evidence from a Single Center”. Anatolian Current Medical Journal 8 (5): 1009-13. https://izlik.org/JA48SY36XT.

EndNote

Cengiz M, Nuransoy Cengiz A, Bozkurt O, İnanç M, Özkan M (September 1, 2026) Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center. Anatolian Current Medical Journal 8 5 1009–1013.

IEEE

[1]M. Cengiz, A. Nuransoy Cengiz, O. Bozkurt, M. İnanç, and M. Özkan, “Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center”, Anatolian Curr Med J / ACMJ / acmj, vol. 8, no. 5, pp. 1009–1013, Sept. 2026, [Online]. Available: https://izlik.org/JA48SY36XT

ISNAD

Cengiz, Muhammet - Nuransoy Cengiz, Ayşe - Bozkurt, Oktay - İnanç, Mevlüde - Özkan, Metin. “Survival Outcomes With First-Line VEGF-Targeted Therapies in Metastatic Renal Cell Carcinoma: Real-World Evidence from a Single Center”. Anatolian Current Medical Journal 8/5 (September 1, 2026): 1009-1013. https://izlik.org/JA48SY36XT.

JAMA

1.Cengiz M, Nuransoy Cengiz A, Bozkurt O, İnanç M, Özkan M. Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center. Anatolian Curr Med J / ACMJ / acmj. 2026;8:1009–1013.

MLA

Cengiz, Muhammet, et al. “Survival Outcomes With First-Line VEGF-Targeted Therapies in Metastatic Renal Cell Carcinoma: Real-World Evidence from a Single Center”. Anatolian Current Medical Journal, vol. 8, no. 5, Sept. 2026, pp. 1009-13, https://izlik.org/JA48SY36XT.

Vancouver

1.Muhammet Cengiz, Ayşe Nuransoy Cengiz, Oktay Bozkurt, Mevlüde İnanç, Metin Özkan. Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center. Anatolian Curr Med J / ACMJ / acmj [Internet]. 2026 Sep. 1;8(5):1009-13. Available from: https://izlik.org/JA48SY36XT